GlassScriptPhysician profile
Ethan Scot Gilde
NPI 1871083378
$9,132.55
in general payments reported to CMS, 2019-2025
52 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $339 · 2021: $1,565 · 2022: $1,682 · 2023: $909 · 2024: $2,006 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,897.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.17 | 2021-2025 | |
| Emd Serono, INC. | $784.99 | 2020-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $680.34 | 2022-2025 | |
| Ucb, INC. | $668.62 | 2021-2025 | Rystiggo, Briviact, Fintepla |
| Genentech USA, INC. | $517.51 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Biogen, INC. | $430.38 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $408.77 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $376.20 | 2019-2024 | Ultomiris |
| Eisai INC. | $300.81 | 2021-2025 | |
| Lundbeck LLC | $289.05 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $263.40 | 2022-2023 | Austedo Xr |
| Sk Life Science, INC. | $247.77 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $234.93 | 2024-2025 | Ponvory |
| Neurocrine Biosciences, INC. | $232.89 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $207.09 | 2020-2024 | Reyvow, Emgality |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $202.06 | 2019-2025 | Rytary, Lyvispah, Crexont |
| Biohaven Pharmaceutical Holding Company LTD. | $185.50 | 2022 | |
| Acorda Therapeutics, INC | $176.88 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.31 | 2024-2025 | Hyqvia |
| Sumitomo Pharma America, INC. | $168.02 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $142.89 | 2021-2025 | Nuplazid |
| Pfizer INC. | $136.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $114.41 | 2021-2025 | Wainua |
| Kyowa Kirin, INC. | $107.32 | 2021-2024 | Nourianz |
| Amgen INC. | $88.03 | 2024 | Uplizna |
| Avanir Pharmaceuticals, INC. | $81.46 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $72.69 | 2021-2022 | |
| Csl Behring | $71.18 | 2021-2024 | Hizentra |
| Octapharma USA, INC. | $66.77 | 2023-2024 | Panzyga |
| Janssen Biotech, INC. | $62.84 | 2025 | |
| Tg Therapeutics, INC. | $58.35 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $53.93 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Livanova USA, INC. | $39.62 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Otsuka America Pharmaceutical, INC. | $39.09 | 2024-2025 | Rexulti |
| Adamas Pharmaceuticals, INC. | $38.69 | 2020-2021 | |
| Celgene Corporation | $36.22 | 2023-2024 | Zeposia |
| Neurelis, INC. | $33.06 | 2020-2025 | Valtoco |
| Medtronic, INC. | $31.95 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $26.67 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $22.66 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.71 | 2025 | Amvuttra |
| Hospira, INC. | $20.21 | 2025 | |
| Cala Health, INC. | $19.98 | 2023 | Cala Trio |
| Mdd US Operations, LLC | $19.86 | 2023 | Gocovri |
| Cycle Pharmaceuticals INC | $19.12 | 2025 | Bafiertam, Tascenso Odt |
| Invivyd INC | $17.25 | 2025 | Pemgarda |
| Jazz Pharmaceuticals INC. | $16.12 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.86 | 2025 | Keveyis |
| Allergan, INC. | $14.24 | 2020 | |
| Genzyme Corporation | $14.07 | 2021 | |
| Axsome Therapeutics, INC. | $13.83 | 2025 | Symbravo |
| Aucta Pharmaceuticals, INC. | $4.62 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Gilde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.